Replies to post #89527 on Biotech Values

[DewDiligence]

I think we’re on the same wavelength. If the Conatus trial design had been up to me, the trial would’ve had four arms (rather then two) as follows:

• CTI-1027 + SoC
• CTI-1027 + ribavirin
• CTI-1027 monotherapy
• SoC control arm

[DewDiligence]

Conatus starts phase-2b trial in HCV null-responders:

http://finance.yahoo.com/news/Conatus-Pharmaceuticals-prnews-802390242.html?x=0&.v=1

This is possibly the oddest HCV program I know of. Conatus, who is private, seems to not quite be sure if CTS-1027 is an antiviral drug or something else. For background, please see the embedded links in #msg-46034554.